NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: ERIS · data 2026-10-31
Eris Lifesciences Ltd
In plain words
Price: 33.5% below its 52-week high of ₹1,740.
Delivery: 45.0% of traded shares were kept for delivery over the last 10 sessions, against 54.8% over the last 60.
Latest results: a net profit of ₹84 cr for the quarter ended Dec 2024 (-18.6% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹3,330 cr |
| Net profit (last 12 months) | ₹708 cr |
| Sales growth, 3 years (yearly) | 22.9% |
| Profit growth, 3 years (yearly) | 17.5% |
At a glance
Promoters 54.1%, pledged 16.9%, institutions 26.5%.
P/E 22.5, P/B 3.9, dividend yield 0.6%. Price relative to earnings and book value (low is cheaper, not better).
ROE 18.3%, ROCE 15.6%, operating margin 26.3%: how much profit it earns on the money it uses.
Debt/equity 0.60, Profit growth 17.5% and sales growth 22.9% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- High return on equity (18.3%).
- Healthy operating margin (26.3%).
- Profit grew 17.5% a year over 3 years.
- Promoters have pledged 16.9% of their shares.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q3 FY25)
ERIS Q3 FY25 results (consolidated figures, as filed on NSE).
Revenue was ₹727.45 crore, up 49.6% YoY and down 1.6% QoQ.
Net profit was ₹83.63 crore, down 18.6% YoY and down 8.7% QoQ.
Operating margin was 34.4% (36.1% a year ago).
EPS was ₹6.15, down 18.5% YoY and down 8.6% QoQ.
ERIS के Q3 FY25 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹727.45 करोड़; पिछले साल की तुलना में 49.6% की बढ़त, पिछली तिमाही की तुलना में 1.6% की गिरावट।
शुद्ध मुनाफ़ा: ₹83.63 करोड़; पिछले साल की तुलना में 18.6% की गिरावट, पिछली तिमाही की तुलना में 8.7% की गिरावट।
ऑपरेटिंग मार्जिन: 34.4% (एक साल पहले 36.1%)।
EPS: ₹6.15; पिछले साल की तुलना में 18.5% की गिरावट, पिछली तिमाही की तुलना में 8.6% की गिरावट।
ERISના Q3 FY25 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹727.45 કરોડ; ગયા વર્ષની સરખામણીએ 49.6% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 1.6% ઘટાડો.
ચોખ્ખો નફો: ₹83.63 કરોડ; ગયા વર્ષની સરખામણીએ 18.6% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 8.7% ઘટાડો.
ઓપરેટિંગ માર્જિન: 34.4% (એક વર્ષ પહેલાં 36.1%).
EPS: ₹6.15; ગયા વર્ષની સરખામણીએ 18.5% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 8.6% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
21/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 10/30: Delivery 47.6% over the last 20 sessions vs 60.5% in the 40 before (0.79x); shares delivered per day 1.26x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 5/15: 2 schemes hold it, about ₹129 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 1/15: Verdict "None", sustained score 36/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend ● Results
- 29 May 26Dividend Dividend ₹7.21 (ex-date) +2.0% next session
- 13 Feb 25Dividend Dividend ₹7.35 (ex-date) -4.1% next session
- 5 Feb 25Results Q3 FY25 results: profit −18.6% YoY +18.0% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Dec 2024 | ₹727 cr | ₹84 cr | -18.6% | 34.4% | 6.15 |
| Sept 2024 | ₹739 cr | ₹92 cr | — | 35.5% | 6.73 |
| Dec 2023 | ₹486 cr | ₹103 cr | — | 36.1% | 7.55 |
| Mar 2023 | ₹403 cr | ₹65 cr | — | 29.5% | 4.81 |
Shareholding trend
| Holder | Jun 2026 | Mar 2026 | Sept 2025 |
|---|---|---|---|
| Promoters | 54.14% | 53.92% | 54.85% |
| Foreign institutions (FII) | 5.75% | 6.39% | 7.21% |
| Domestic institutions (DII) | 20.72% | 20.35% | 19.36% |
| Mutual funds | 18.88% | 18.22% | 17.33% |
| Retail investors | 2.65% | 2.61% | 2.57% |
| Number of shareholders | 50,798 | 51,656 | 59,438 |
Common questions
What was Eris Lifesciences Ltd's latest quarterly profit?
Eris Lifesciences Ltd reported a net profit of ₹84 cr for the quarter ended Dec 2024 (-18.6% on the same quarter a year earlier), on revenue of ₹727 cr.
How much do promoters hold in Eris Lifesciences Ltd?
Promoters held 54.14% of Eris Lifesciences Ltd at the end of Jun 2026, with 16.85% of promoter shares pledged.
Is Eris Lifesciences Ltd debt-free?
Its latest reported debt-to-equity ratio is 0.6.
What is Eris Lifesciences Ltd's P/E ratio?
About 22.5, based on the last 12 months' earnings and a price of ₹1,156.4 (data 2026-10-31).
What is the 52-week high and low of Eris Lifesciences Ltd?
The 52-week high is ₹1,740 and the 52-week low is ₹1,069.
Mutual funds holding Eris Lifesciences Ltd
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 2 schemes holding about ₹129 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| Mirae Asset Healthcare Fund | Mirae Asset Mutual Fund | 2.39% | ₹84 cr |
| ADITYA BIRLA SUN LIFE AGGRESSIVE HYBRID FUND | Aditya Birla Sun Life Mutual Fund | 0.66% | ₹45 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Eris Lifesciences Ltd | ₹1,156.4 | ₹16,088 cr | 22.5 | 3.9 | 18.3% | 15.6% | 0.6 | -29.0% |
| Cohance Lifesciences Ltd | ₹444.3 | ₹17,005 cr | 161 | 4.4 | 6.4% | 4.6% | 0.1 | -44.0% |
| PFIZER LIMITED | ₹3,687.8 | ₹16,867 cr | 23 | — | 17.2% | 20% | 0.02 | -30.0% |
| AstraZeneca Pharma India Limited | ₹6,364.5 | ₹15,918 cr | 93.8 | — | 23.9% | 25.5% | 0.13 | -31.8% |
| Alembic Pharmaceuticals Limited | ₹797.85 | ₹15,682 cr | 22.6 | — | 12.3% | 11.8% | 0.25 | -11.4% |
| NATCO Pharma Limited | ₹782.4 | ₹15,350 cr | 12.4 | — | 16.9% | 15.6% | 0.08 | -4.8% |
Compare ERIS with COHANCE in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ERIS in NSE Scanner →